Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)
NCT ID: NCT07094711
Last Updated: 2025-08-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
48 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-30
Study Completion Date
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to find out if the Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine can be used safely to treat Mycobacterium avium complex (MAC) lung disease.
Researchers will compare responses from patients with MAC lung disease after receiving an injection of BCG or placebo (a look-alike substance that contains no drug)
Participants in the study:
* Receive a BCG or placebo injection at UVA study center on Day 0
* Come to UVA study center on Day 60
* Come to UVA study center at the end of the study
* Answer surveys and questionnaires about how you are doing
* Have blood drawn 3 times, on injection day, day 60, and at end of study
* Give the study team personal and demographic information
* Discuss any new symptoms with the study team
* Provide monthly sputum samples per usual care
Researchers will compare responses from patients with MAC lung disease after receiving an injection of BCG or placebo (a look-alike substance that contains no drug)
Participants in the study:
* Receive a BCG or placebo injection at UVA study center on Day 0
* Come to UVA study center on Day 60
* Come to UVA study center at the end of the study
* Answer surveys and questionnaires about how you are doing
* Have blood drawn 3 times, on injection day, day 60, and at end of study
* Give the study team personal and demographic information
* Discuss any new symptoms with the study team
* Provide monthly sputum samples per usual care
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using BCG Vaccine to Understand Tuberculosis Infection
NCT05820594
Tuberculosis
UNKNOWN
NA
A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers
NCT00480688
TB
COMPLETED
PHASE1
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers
NCT00480714
TB
COMPLETED
NA
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
NCT00654316
TB
COMPLETED
PHASE1
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
NCT00396370
Tuberculosis
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mycobacterium avium complex (MAC) lung disease (LD) is an increasingly prevalent condition in the United States. Treatment involves administration of multiple antibiotics for at least 12 months and many patients still fail, or infection recurs. New therapeutic strategies are needed. We hypothesize that Mycobacterium bovis Bacillus Calmette Guerin (BCG) will have microbiologic activity against MAC during lung disease, because of
* Its mycobacterium antigens shared with MAC (1).
* In vitro evidence that BCG stimulates MAC-specific immune responses in mice and humans (2, 3).
* In vivo evidence that BCG reduces MAC in mice with established infection (4). Clinical evidence for BCG protection against MAC infection in HIV patients and in children (5, 6).
Objectives:
The primary objective is to determine the safety and immunogenicity of BCG against MAC lung disease after intradermal vaccination with BCG or placebo.
The secondary objectives include:
* the microbiologic efficacy of BCG compared to placebo.
* to determine if BCG is superior to placebo in reducing all-cause respiratory illness requiring additional antibiotics, healthcare assessment, or admission.
Endpoints:
Primary endpoints:
* Safety and tolerability of intradermal BCG (TICE®) in this patient population, compared to placebo, assessed by weekly questionnaire of adverse events over 12 weeks.
* Serious adverse events related to the intradermal BCG over 12 months.
* Immunogenicity of BCG as measured by the change in BCG-induced IFN-γ production in PBMCs 60 days after vaccination, compared to placebo.
Secondary endpoints:
* Proportion of monthly sputum cultures positive for MAC after BCG vaccine or placebo over 24 months.
* Immunogenicity of BCG on MAC-specific IFN-γ responses.
* Proportion of patients with MAC culture conversion and MAC recurrence within 24 months.
* Rates of all-cause respiratory illness requiring additional antibiotics, healthcare assessment, or admission over 24 months.
* Symptom scores using the Quality of Life- Bronchiectasis Respiratory (QOL-BR) questionnaire over 24 months.
* Adverse Events of Special Interest (local/systemic M. bovis BCG infection) over 24 months.
Exploratory endpoints:
* Assess the efficacy of BCG versus placebo on chest imaging score.
* While the study is not powered to detect differences among subgroups, we will enumerate whether above endpoints are modified among these patient subgroups: cavitary versus non-cavitary disease, age, gender, the species of MAC infection, and those with higher IFN-γ responses.
* Assess PBMC cytokine responses beyond IFN-γ.
* Assess durability of immune responses at 24 months.
Study Population:
We aim to enroll a total of 48 participants with MAC, of which 24 will be randomized to receive each of BCG and placebo.
* Its mycobacterium antigens shared with MAC (1).
* In vitro evidence that BCG stimulates MAC-specific immune responses in mice and humans (2, 3).
* In vivo evidence that BCG reduces MAC in mice with established infection (4). Clinical evidence for BCG protection against MAC infection in HIV patients and in children (5, 6).
Objectives:
The primary objective is to determine the safety and immunogenicity of BCG against MAC lung disease after intradermal vaccination with BCG or placebo.
The secondary objectives include:
* the microbiologic efficacy of BCG compared to placebo.
* to determine if BCG is superior to placebo in reducing all-cause respiratory illness requiring additional antibiotics, healthcare assessment, or admission.
Endpoints:
Primary endpoints:
* Safety and tolerability of intradermal BCG (TICE®) in this patient population, compared to placebo, assessed by weekly questionnaire of adverse events over 12 weeks.
* Serious adverse events related to the intradermal BCG over 12 months.
* Immunogenicity of BCG as measured by the change in BCG-induced IFN-γ production in PBMCs 60 days after vaccination, compared to placebo.
Secondary endpoints:
* Proportion of monthly sputum cultures positive for MAC after BCG vaccine or placebo over 24 months.
* Immunogenicity of BCG on MAC-specific IFN-γ responses.
* Proportion of patients with MAC culture conversion and MAC recurrence within 24 months.
* Rates of all-cause respiratory illness requiring additional antibiotics, healthcare assessment, or admission over 24 months.
* Symptom scores using the Quality of Life- Bronchiectasis Respiratory (QOL-BR) questionnaire over 24 months.
* Adverse Events of Special Interest (local/systemic M. bovis BCG infection) over 24 months.
Exploratory endpoints:
* Assess the efficacy of BCG versus placebo on chest imaging score.
* While the study is not powered to detect differences among subgroups, we will enumerate whether above endpoints are modified among these patient subgroups: cavitary versus non-cavitary disease, age, gender, the species of MAC infection, and those with higher IFN-γ responses.
* Assess PBMC cytokine responses beyond IFN-γ.
* Assess durability of immune responses at 24 months.
Study Population:
We aim to enroll a total of 48 participants with MAC, of which 24 will be randomized to receive each of BCG and placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Mycobacterium Avium-intracellulare Infection
Mycobacterium Infections, Nontuberculous
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Standard two-sample comparisons will be used to compare changes in immunogenicity.
The number and type of adverse events will be tabulated by treatment group. Chi-squared tests will be used to compare the groups on the proportion of patients in each group experiencing severe adverse events. Standard one-side, two-sample confidence intervals will be used to summarize the difference in proportions between the groups.
Logistic regression with generalized estimating equations (GEE) will be used for the proportion of monthly sputum cultures positive for MAC after BCG vaccination or placebo.
The number and type of adverse events will be tabulated by treatment group. Chi-squared tests will be used to compare the groups on the proportion of patients in each group experiencing severe adverse events. Standard one-side, two-sample confidence intervals will be used to summarize the difference in proportions between the groups.
Logistic regression with generalized estimating equations (GEE) will be used for the proportion of monthly sputum cultures positive for MAC after BCG vaccination or placebo.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active BCG
Biological/Vaccine: Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine
Group Type
ACTIVE_COMPARATOR
Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine
Intervention Type
BIOLOGICAL
Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.
Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally.
Placebo
preservative-free saline
Group Type
PLACEBO_COMPARATOR
preservative-free saline
Intervention Type
DRUG
Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine
Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.
Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally.
Intervention Type
BIOLOGICAL
preservative-free saline
Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
TICE® BCG
saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
1. Male or female aged ≥18 years
2. Mycobacterium avium complex lung disease as evidenced by diagnosis or treatment for MAC lung disease by pulmonologist or infectious disease physician in the medical record. The following data will be extracted from the medical record:
1. History of at least 2 MAC positive respiratory cultures, one of which is within 1 year of enrollment. In the event a MAC positive culture is from bronchial lavage or biopsy, one culture rather than 2 will meet criteria.
2. Respiratory and/or constitutional symptoms consistent with MAC lung disease
3. Nodular or cavitary opacities on chest radiograph or bronchiectasis with multiple small nodules on high-resolution computed tomography
3. Provision of signed and dated informed consent form
4. Stated willingness to comply with all study procedures
5. Women of childbearing potential (WOCBP) (i.e., fertile following menarche and until becoming postmenopausal unless permanently sterile) agree to practice a highly effective method of birth control from Day 0 to at least 90 days after study intervention. Some examples of acceptable birth controls are:
1. True abstinence (refraining from heterosexual intercourse during the entire study),
2. Copper intrauterine device (IUD),
3. Hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill \[combined with barrier method\]), exclusive homosexual relationship) sole male partner who has undergone surgical sterilization
1. Male or female aged ≥18 years
2. Mycobacterium avium complex lung disease as evidenced by diagnosis or treatment for MAC lung disease by pulmonologist or infectious disease physician in the medical record. The following data will be extracted from the medical record:
1. History of at least 2 MAC positive respiratory cultures, one of which is within 1 year of enrollment. In the event a MAC positive culture is from bronchial lavage or biopsy, one culture rather than 2 will meet criteria.
2. Respiratory and/or constitutional symptoms consistent with MAC lung disease
3. Nodular or cavitary opacities on chest radiograph or bronchiectasis with multiple small nodules on high-resolution computed tomography
3. Provision of signed and dated informed consent form
4. Stated willingness to comply with all study procedures
5. Women of childbearing potential (WOCBP) (i.e., fertile following menarche and until becoming postmenopausal unless permanently sterile) agree to practice a highly effective method of birth control from Day 0 to at least 90 days after study intervention. Some examples of acceptable birth controls are:
1. True abstinence (refraining from heterosexual intercourse during the entire study),
2. Copper intrauterine device (IUD),
3. Hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill \[combined with barrier method\]), exclusive homosexual relationship) sole male partner who has undergone surgical sterilization
Exclusion Criteria
Selection of study participants will be equitable, but an individual who meets any of the following criteria will be excluded from participation in this study:
1. Currently receiving antibiotics prescribed for their MAC lung disease
2. Having received any antibacterial antibiotics within the past 14 days prior to study vaccination, day 0
3. Known allergy, intolerance or other contraindication to isoniazid or rifampin or ethambutol
4. Expectation of starting anti-MAC lung disease antibiotics in the next 2 months per patient or their physician
5. Persons with congenital or acquired immune deficiencies (e.g., HIV infection; leukemia, lymphoma, or cancer therapy within the past 2 years; immunosuppressive therapy such as anti B cell depleting therapies, corticosteroids (\>20 mg/day for \> 14 days), dupilumab, elivaldogene, etrasimod, cytotoxic chemotherapy, miscellaneous oncologic agents, therapeutic immunosuppressant agents, methotrexate, teplizumab, tezepelumab, tildrakizumab, tralokinumab, ustekinumab). Persons with lung and other solid organ transplants/hematologic stem cell transplants who may be contraindicated to receive a live vaccine. Point of care HIV testing must be negative at baseline.
6. Prior BCG Vaccination. If unknown Bcgatlas.org shall be consulted for local vaccination administration policies.
7. Known pregnancy at the time of screening or breastfeeding at the time of enrollment (pregnancy test negative at baseline if applicable)
8. Cystic fibrosis
9. Active tuberculosis: Active tuberculosis (respiratory AFB culture growing Mycobacterium tuberculosis complex within the past 4 months).
10. Known exposure to a case of active pulmonary tuberculosis within 10 weeks of enrollment
11. Known prior hypersensitivity reaction to BCG or any component of the BCG vaccine
12. Received live injectable vaccine within 28 days of day 0 study vaccination
13. Any condition in the opinion of the investigator that may confound the study endpoints Note that colonization or co-infection with other nontuberculous mycobacteria is not exclusionary, as MAC will be the endpoint.
1. Currently receiving antibiotics prescribed for their MAC lung disease
2. Having received any antibacterial antibiotics within the past 14 days prior to study vaccination, day 0
3. Known allergy, intolerance or other contraindication to isoniazid or rifampin or ethambutol
4. Expectation of starting anti-MAC lung disease antibiotics in the next 2 months per patient or their physician
5. Persons with congenital or acquired immune deficiencies (e.g., HIV infection; leukemia, lymphoma, or cancer therapy within the past 2 years; immunosuppressive therapy such as anti B cell depleting therapies, corticosteroids (\>20 mg/day for \> 14 days), dupilumab, elivaldogene, etrasimod, cytotoxic chemotherapy, miscellaneous oncologic agents, therapeutic immunosuppressant agents, methotrexate, teplizumab, tezepelumab, tildrakizumab, tralokinumab, ustekinumab). Persons with lung and other solid organ transplants/hematologic stem cell transplants who may be contraindicated to receive a live vaccine. Point of care HIV testing must be negative at baseline.
6. Prior BCG Vaccination. If unknown Bcgatlas.org shall be consulted for local vaccination administration policies.
7. Known pregnancy at the time of screening or breastfeeding at the time of enrollment (pregnancy test negative at baseline if applicable)
8. Cystic fibrosis
9. Active tuberculosis: Active tuberculosis (respiratory AFB culture growing Mycobacterium tuberculosis complex within the past 4 months).
10. Known exposure to a case of active pulmonary tuberculosis within 10 weeks of enrollment
11. Known prior hypersensitivity reaction to BCG or any component of the BCG vaccine
12. Received live injectable vaccine within 28 days of day 0 study vaccination
13. Any condition in the opinion of the investigator that may confound the study endpoints Note that colonization or co-infection with other nontuberculous mycobacteria is not exclusionary, as MAC will be the endpoint.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric R. Houpt, MD
Professor and Chief, Division of Infectious Diseases and International Health, Medicine: Infectious Diseases and International Health
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Health
Charlottesville, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Blazevic A, Edwards RL, Xia M, Eickhoff CS, Hamzabegovic F, Meza KA, Ning H, Tennant J, Mosby KJ, Ritchie JC, Girmay T, Lai L, McCullough M, Beck A, Kelley C, Edupuganti S, Kabbani S, Buchanan W, Makhene MK, Voronca D, Cherikh S, Goll JB, Rouphael NG, Mulligan MJ, Hoft DF. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo. J Infect Dis. 2024 May 15;229(5):1498-1508. doi: 10.1093/infdis/jiad441.
Reference Type
BACKGROUND
Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care. 1999 Oct;22(10):1703-7. doi: 10.2337/diacare.22.10.1703.
Reference Type
BACKGROUND
Bricks LF. [Percutaneous or intradermal BCG vaccine?]. J Pediatr (Rio J). 2004 Mar-Apr;80(2):93-8. Portuguese.
Reference Type
BACKGROUND
Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014 Aug 5;349:g4643. doi: 10.1136/bmj.g4643.
Reference Type
BACKGROUND
Koekenbier EL, Fohse K, van de Maat JS, Oosterheert JJ, van Nieuwkoop C, Hoogerwerf JJ, Grobusch MP, van den Bosch MAAJ, van de Wijgert JHH, Netea MG, Rosendaal FR, Bonten MJM, Werkhoven CHHV; BCG-PRIME study group. Bacillus Calmette-Guerin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin Microbiol Infect. 2023 Jun;29(6):781-788. doi: 10.1016/j.cmi.2023.01.019. Epub 2023 Feb 2.
Reference Type
BACKGROUND
Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollmann TR, Lacerda MVG, Lee KJ, Lucas M, Lynn DJ, Manning L, Marshall HS, McDonald E, Munns CF, Nicholson S, O'Connell A, de Oliveira RD, Perlen S, Perrett KP, Prat-Aymerich C, Richmond PC, Rodriguez-Bano J, Dos Santos G, da Silva PV, Teo JW, Villanueva P, Warris A, Wood NJ, Davidson A, Curtis N; BRACE Trial Consortium Group. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med. 2023 Apr 27;388(17):1582-1596. doi: 10.1056/NEJMoa2212616.
Reference Type
BACKGROUND
Dionato FAV, Jalalizadeh M, Buosi K, Visacri MB, Dal Col LSB, Giacomelli CF, Leme PAF, Maia CL, Moriel P, Reis LO. BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial. Vaccine. 2022 Jul 30;40(32):4603-4608. doi: 10.1016/j.vaccine.2022.06.039. Epub 2022 Jun 20.
Reference Type
BACKGROUND
Tsilika M, Taks E, Dolianitis K, Kotsaki A, Leventogiannis K, Damoulari C, Kostoula M, Paneta M, Adamis G, Papanikolaou I, Stamatelopoulos K, Bolanou A, Katsaros K, Delavinia C, Perdios I, Pandi A, Tsiakos K, Proios N, Kalogianni E, Delis I, Skliros E, Akinosoglou K, Perdikouli A, Poulakou G, Milionis H, Athanassopoulou E, Kalpaki E, Efstratiou L, Perraki V, Papadopoulos A, Netea MG, Giamarellos-Bourboulis EJ. ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk. Front Immunol. 2022 Jul 5;13:873067. doi: 10.3389/fimmu.2022.873067. eCollection 2022.
Reference Type
BACKGROUND
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Dominguez-Andres J, Kyriazopoulou E, Gkavogianni T, Adami ME, Damoraki G, Koufargyris P, Karageorgos A, Bolanou A, Koenen H, van Crevel R, Droggiti DI, Renieris G, Papadopoulos A, Netea MG. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell. 2020 Oct 15;183(2):315-323.e9. doi: 10.1016/j.cell.2020.08.051. Epub 2020 Sep 1.
Reference Type
BACKGROUND
Villanueva P, Crawford NW, Garcia Croda M, Collopy S, Araujo Jardim B, de Almeida Pinto Jardim T, Marshall H, Prat-Aymerich C, Sawka A, Sharma K, Troeman D, Wadia U, Warris A, Wood N, Messina NL, Curtis N, Pittet LF. Safety of BCG vaccination and revaccination in healthcare workers. Hum Vaccin Immunother. 2023 Aug 1;19(2):2239088. doi: 10.1080/21645515.2023.2239088.
Reference Type
BACKGROUND
Fritschi N, Curtis N, Ritz N. Bacille Calmette Guerin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects. Paediatr Respir Rev. 2020 Nov;36:57-64. doi: 10.1016/j.prrv.2020.08.004. Epub 2020 Aug 20.
Reference Type
BACKGROUND
Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011 Mar;8(3):e1001012. doi: 10.1371/journal.pmed.1001012. Epub 2011 Mar 22.
Reference Type
BACKGROUND
Dow CT, Kidess L. BCG Vaccine-The Road Not Taken. Microorganisms. 2022 Sep 27;10(10):1919. doi: 10.3390/microorganisms10101919.
Reference Type
BACKGROUND
Greinert U, Schlaak M, Rusch-Gerdes S, Flad HD, Ernst M. Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J Clin Immunol. 2000 Nov;20(6):445-52. doi: 10.1023/a:1026407815946.
Reference Type
BACKGROUND
Gramegna A, Lombardi A, Lore NI, Amati F, Barone I, Azzara C, Cirillo D, Aliberti S, Gori A, Blasi F. Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review. Front Immunol. 2022 Jun 28;13:927049. doi: 10.3389/fimmu.2022.927049. eCollection 2022.
Reference Type
BACKGROUND
Winthrop K, Rivera A, Engelmann F, Rose S, Lewis A, Ku J, Bermudez L, Messaoudi I. A Rhesus Macaque Model of Pulmonary Nontuberculous Mycobacterial Disease. Am J Respir Cell Mol Biol. 2016 Feb;54(2):170-6. doi: 10.1165/rcmb.2015-0256RC.
Reference Type
BACKGROUND
Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005 Aug;3(8):656-62. doi: 10.1038/nrmicro1211.
Reference Type
BACKGROUND
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
Reference Type
BACKGROUND
Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004 Aug;126(2):566-81. doi: 10.1378/chest.126.2.566.
Reference Type
BACKGROUND
Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6. doi: 10.1164/rccm.201111-2016OC. Epub 2012 Feb 3.
Reference Type
BACKGROUND
Schildknecht KR, Pratt RH, Feng PI, Price SF, Self JL. Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):297-303. doi: 10.15585/mmwr.mm7212a1.
Reference Type
BACKGROUND
Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015. Ann Am Thorac Soc. 2020 Feb;17(2):178-185. doi: 10.1513/AnnalsATS.201804-236OC.
Reference Type
BACKGROUND
Strollo SE, Adjemian J, Adjemian MK, Prevots DR. The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States. Ann Am Thorac Soc. 2015 Oct;12(10):1458-64. doi: 10.1513/AnnalsATS.201503-173OC.
Reference Type
BACKGROUND
Orujyan D, Narinyan W, Rangarajan S, Rangchaikul P, Prasad C, Saviola B, Venketaraman V. Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections. Vaccines (Basel). 2022 Mar 3;10(3):390. doi: 10.3390/vaccines10030390.
Reference Type
BACKGROUND
Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. J Infect Dis. 2018 Jul 24;218(5):679-687. doi: 10.1093/infdis/jiy207.
Reference Type
BACKGROUND
Rais M, Abdelaal H, Reese VA, Ferede D, Larsen SE, Pecor T, Erasmus JH, Archer J, Khandhar AP, Cooper SK, Podell BK, Reed SG, Coler RN, Baldwin SL. Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis (Edinb). 2023 Jan;138:102302. doi: 10.1016/j.tube.2022.102302. Epub 2022 Dec 27.
Reference Type
BACKGROUND
Abate G, Hamzabegovic F, Eickhoff CS, Hoft DF. BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity. Front Immunol. 2019 Feb 19;10:234. doi: 10.3389/fimmu.2019.00234. eCollection 2019.
Reference Type
BACKGROUND
Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, Ordway D, Henao-Tamayo M, Podell BK, Baldwin SL, Coler RN. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Sci Rep. 2021 Apr 27;11(1):9040. doi: 10.1038/s41598-021-88291-8.
Reference Type
BACKGROUND
Harboe M, Mshana RN, Closs O, Kronvall G, Axelsen NH. Cross-reactions between mycobacteria. II. Crossed immunoelectrophoretic analysis of soluble antigens of BCG and comparison with other mycobacteria. Scand J Immunol. 1979;9(2):115-24. doi: 10.1111/j.1365-3083.1979.tb02713.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
302296Boost
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Role of BCG as Booster Vaccination
NCT02175420
COMPLETED
NA
Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults
NCT01829490
COMPLETED
PHASE1
BCG Vaccination to Prevent COVID-19
NCT04632537
WITHDRAWN
PHASE3
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
NCT01879163
COMPLETED
PHASE1
Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.
NCT02013245
COMPLETED
PHASE1
BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)
NCT04534803
WITHDRAWN
PHASE3
Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults
NCT02729571
COMPLETED
PHASE1/PHASE2
A Study of the Interaction Between BCG And MenC Immunisation: BAM
NCT02002156
COMPLETED
PHASE4
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
NCT00653770
COMPLETED
PHASE1
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
NCT00653627
COMPLETED
PHASE1
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
NCT04884308
COMPLETED
PHASE2
BCG Vaccine for Health Care Workers as Defense Against COVID 19
NCT04348370
COMPLETED
PHASE4
A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A
NCT01194180
COMPLETED
PHASE1
Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine
NCT00800670
TERMINATED
PHASE1
Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents
NCT02378207
COMPLETED
PHASE1
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
NCT00427830
COMPLETED
PHASE1
Aerosol BCG Challenge Trial in Healthy UK Adults
NCT02709278
COMPLETED
PHASE1
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route
NCT01497769
COMPLETED
PHASE1
Clinical Study of BCG Vaccine for Intradermal Injection
NCT04563273
COMPLETED
PHASE1
Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers
NCT04777721
COMPLETED
PHASE1
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
NCT05507671
ACTIVE_NOT_RECRUITING
PHASE3
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
NCT04453293
TERMINATED
PHASE3
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
NCT05547464
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
γ-irradiated BCG to Train Innate Immunity
NCT02259608
COMPLETED
NA
Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans
NCT06845358
WITHDRAWN
PHASE1